Our data argue that the CAM1615HER2 TriKE should be tested clinically next in ovarian cancer and other solid tumor settings where HER2 overexpression is present (breast, lung, etc.)with the hope of providing an alternative approach to reduce mortality in these setting. Here, ERBB2 is linked to ovarian carcinoma.